The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Open accessAbstract
The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available. Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CCLE dataset has previously been used to identify biomarkers for drug resistance and susceptibility (Barretina et al., 2012).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Barretina et al., 2012
In the citing paper
“JDQ443 antiproliferative activity was assessed by a high-throughput cell viability assay in a large panel of KRASG12C-mutated (N = 17) and non–G12C-mutated (N = 225) cell lines from the Cancer Cell Line Encyclopedia (29). JDQ443 demonstrated potent antiproliferative activity selectively toward the KRASG12C-mutated lines (Fig. 2A and B).”
In the citing paper
“However, large-scale drug sensitivity studies using the MEK and ERK inhibitors did not reveal the same degree of selectivity in KRAS mutant cells (69, 70) (Figure 4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [69]
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [151]
In the citing paper
“interrogation of the expression data from the cancer cell line encyclopedia20 (CCLE) database revealed that classical SCLC cell lines have significantly reduced levels of EGFR mRNA compared with adenocarcinoma cell lines”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [20]
In the citing paper
“Other expression datasets integrated into the latest version are the Cancer Cell Line Encyclopedia (16) and cell perturbation expression data from the Library of Integrated Network-Based Cellular Signatures (17).”
From TCRD and pharos 2021: mining the human proteome for disease biology (2021) · cites this paper as [16]
In the citing paper
“The Passport model name is accompanied by synonyms and most importantly unique identifiers utilized by established resources such as Research Resource Identifiers (RRID) (19), the Catalogue of Somatic Mutations in Cancer (COSMIC) (20) and CCLE (6) to aid data integration and alignment.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 978
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,107
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Meric‐Bernstam, F., Johnson, A. M., Holla, V. R., Bailey, A. M., Brusco, L., Chen, K., Routbort, M. J., Patel, K. P., Zeng, J., Kopetz, S., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv098 · Cited by 202
Noncanonical open reading frames encode functional proteins essential for cancer cell survival
Prensner, J. R., Enache, O. M., Luria, V., Krug, K., Clauser, K. R., Dempster, J. M., Karger, A., Wang, L., Stumbraite, K., Wang, V. M., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00806-2 · Cited by 201
Self-citationDeep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data
Chen, J., Wang, X., Ma, A., Wang, Q., Liu, B., Li, L., Xu, D. H., & Ma, Q. (2022) · Nature Communications · doi:10.1038/s41467-022-34277-7 · Cited by 207
An automated fitting procedure and software for dose-response curves with multiphasic features
Veroli, G. Y. D., Fornari, C., Goldlust, I. S., Mills, G., Koh, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2015) · Scientific Reports · doi:10.1038/srep14701 · Cited by 201
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 199
A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response
Gambardella, G., Viscido, G., Tumaini, B., Isacchi, A., Bosotti, R., & di Bernardo, D. (2022) · Nature Communications · doi:10.1038/s41467-022-29358-6 · Cited by 204
van der Meer, D., Barthorpe, S., Yang, W., Lightfoot, H., Hall, C., Gilbert, J., Francies, H. E., & Garnett, M. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky872 · Cited by 195
Drug-induced adverse events prediction with the LINCS L1000 data
Wang, Z., Clark, N. R., & Ma’ayan, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw168 · Cited by 194
Gutschner, T., Hämmerle, M., Pazaitis, N., Bley, N., Fiškin, E., Uckelmann, H. J., Heim, A., Groβ, M., Hofmann, N., Geffers, R., et al. (2014) · Hepatology · doi:10.1002/hep.26997 · Cited by 194
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Chen, Z., Li, J., Lin, S., Cao, C., Gimbrone, N. T., Yang, R., Fu, D., Carper, M. B., Haura, E. B., Schabath, M. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85250 · Cited by 192
Wagle, M.-C., Kirouac, D. C., Klijn, C. N., Liu, B., Mahajan, S., Junttila, M. R., Moffat, J. G., Merchant, M. A., Huw, L. Y., Wongchenko, M. J., et al. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0051-4 · Cited by 194
Smith, I. C. P., Greenside, P., Natoli, T. E., Lahr, D. L., Wadden, D., Tirosh, I., Narayan, R., Root, D. E., Golub, T. R., Subramanian, A., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2003213 · Cited by 197
Self-citation5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis
Jin, S. S., Cojocari, D., Purkal, J. J., Popovic, R., Talaty, N. N., Yu, X. H., Solomon, L. R., Boghaert, E. R., Leverson, J. D., & Phillips, D. C. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1900 · Cited by 205
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Nabet, B. Y., Hamidi, H., Lee, M. C., Banchereau, R., Morris, S., Adler, L., Gayevskiy, V., Elhossiny, A. M., Srivastava, M. K., Patil, N. S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.010 · Cited by 196
Zhang, W., Mao, J., Zhu, W., Jain, A. K., Liu, K., Brown, J. B., & Karpen, G. H. (2016) · Nature Communications · doi:10.1038/ncomms12619 · Cited by 195
Targeted inhibition of the COP9 signalosome for treatment of cancer
Schlierf, A., Altmann, E., Quancard, J., Jefferson, A. B., Assenberg, R., Renatus, M., Jones, M. D., Hassiepen, U., Schaefer, M., Kiffe, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13166 · Cited by 188
Self-citationInosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers
Huang, F., Ni, M., Chalishazar, M. D., Huffman, K. E., Kim, J., Cai, L., Shi, X., Cai, F., Zacharias, L. G., Ireland, A. S., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.005 · Cited by 188
ONECUT2 Is a Targetable Master Regulator of Lethal Prostate Cancer That Suppresses the Androgen Axis
Rotinen, M., You, S., Yang, J., Coetzee, S. G., Reis-Sobreiro, M., Huang, W., Huang, F., Pan, X., Yáñez, A., Hazelett, D. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0241-1 · Cited by 192
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O. E., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S. M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 194
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D., & Lu, X. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0378 · Cited by 195
Lewis, J. E., & Kemp, M. L. (2021) · Nature Communications · doi:10.1038/s41467-021-22989-1 · Cited by 187
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189
A self‐enforcing CD 44s/ ZEB 1 feedback loop maintains EMT and stemness properties in cancer cells
Preca, B., Bajdak-Rusinek, K., Mock, K., Sundararajan, V., Pfannstiel, J., Maurer, J., Wellner, U. F., Hopt, U. T., Brummer, T., Brabletz, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29642 · Cited by 185
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Wang, W., Kandimalla, R., Huang, H., Zhu, L., Li, Y., Gao, F., Goel, A., & Wang, X. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.002 · Cited by 192
Landa, I., Pozdeyev, N. V., Korch, C. T., Marlow, L. A., Smallridge, R. C., Copland, J. A., Henderson, Y. C., Lai, S. Y., Clayman, G. L., Onoda, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2953 · Cited by 188
Deep learning for drug repurposing: Methods, databases, and applications
Pan, X., Lin, X., Cao, D., Zeng, X., Yu, P. S., He, L., Nussinov, R., & Cheng, F. (2022) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1597 · Cited by 202
ProteomicsDB: a multi-omics and multi-organism resource for life science research
Samaras, P., Schmidt, T., Frejno, M., Gessulat, S., Reinecke, M., Jarząb, A., Zecha, J., Mergner, J., Giansanti, P., Ehrlich, H., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz974 · Cited by 187
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
Morel, A., Ginestier, C., Pommier, R. M., Cabaud, O., Ruiz, E. M., Wicinski, J., Devouassoux‐Shisheboran, M., Combaret, V., Finetti, P., Chassot, C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4323 · Cited by 189
Janoušková, H., Tekle, G. E., Bellini, E., Udeshi, N. D., Rinaldi, A. M., Ulbricht, A., Bernasocchi, T., Civenni, G., Losa, M., Svinkina, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4372 · Cited by 185
Self-citationTargeting pan-essential genes in cancer: Challenges and opportunities
Chang, L., Ruiz, P. A., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 188
Self-citationACSL4 and polyunsaturated lipids support metastatic extravasation and colonization
Wang, Y., Hu, M., Cao, J., Wang, F., Han, J. R., Wu, T. W., Li, L., Yu, J., Fan, Y., Xie, G., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.047 · Cited by 197
Self-citationCaruso, S., Calatayud, A.-L., Pilet, J., Bella, T. L., Rekik, S., Imbeaud, S., Letouzé, É., Meunier, L., Bayard, Q., Rohr‐Udilova, N., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.001 · Cited by 186
Expanding the computational toolbox for mining cancer genomes
Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 188
Evolution and dynamics of pancreatic cancer progression
Yachida, S., & Iacobuzio–Donahue, C. A. (2013) · Oncogene · doi:10.1038/onc.2013.29 · Cited by 185
Zhong, W., Myers, J. S., Wang, F., Wang, K., Lucas, J., Rosfjord, E. C., Lucas, J., Hooper, A. T., Yang, S., Lemon, L., et al. (2020) · BMC Genomics · doi:10.1186/s12864-019-6344-3 · Cited by 194
Wu, Y., & Xie, L. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.12.030 · Cited by 220
Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth
Scalise, M., Pochini, L., Galluccio, M., Console, L., & Indiveri, C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00306 · Cited by 183
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 185
Comprehensive Characterization of Alternative Polyadenylation in Human Cancer
Xiang, Y., Ye, Y., Lou, Y., Yang, Y., Cai, C. C., Zhang, Z., Mills, T., Chen, N., Kim, Y.-J., Ozguc, F. M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx223 · Cited by 183
Applications of organoids for cancer biology and precision medicine
Lo, Y.-H., Karlsson, K., & Kuo, C. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0102-y · Cited by 182
Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Best, S. A., Gubser, P. M., Sethumadhavan, S., Kersbergen, A. J., Abril, Y. L. N., Goldford, J. E., Sellers, K., Abeysekera, W., Garnham, A. L., McDonald, J. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.003 · Cited by 192
Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P. K., Martínez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D. M., Sayles, L. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14294 · Cited by 179
Targeting the DNA Repair Pathway in Ewing Sarcoma
Stewart, E. A., Goshorn, D. R., Bradley, C. L., Griffiths, L. M., Benavente, C. A., Twarog, N. R., Miller, G. M., Caufield, W. V., Freeman, B. B., Bahrami, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.028 · Cited by 183
Dr.VAE: improving drug response prediction via modeling of drug perturbation effects
Rampášek, L., Hidru, D., Smirnov, P., Haibe‐Kains, B., & Goldenberg, A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz158 · Cited by 174
Metabolomics and Multi-Omics Integration: A Survey of Computational Methods and Resources
Eicher, T., Kinnebrew, G. H., Patt, A. C., Spencer, K., Ying, K. L., Ma, Q., Machiraju, R., & Mathé, E. A. (2020) · Metabolites · doi:10.3390/metabo10050202 · Cited by 191
Miller, S. A., Policastro, R. A., Sriramkumar, S., Lai, T., Huntington, T. D., Ladaika, C. A., Kim, D.-H., Hao, C., Zentner, G. E., & O’Hagan, H. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3562 · Cited by 174
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 184
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Sos, M. L., Dietlein, F., Peifer, M., Schöttle, J., Balke‐Want, H., Müller, C., Koker, M., Richters, A., Heynck, S., Malchers, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207310109 · Cited by 179
Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder
Bian, Y., Li, L., Dong, M., Liu, X., Kaneko, T., Cheng, K., Liu, H., Voss, C., Cao, X., Wang, Y., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2178 · Cited by 177
Wang, L., Li, X., Zhang, L., & Gao, Q. (2017) · BMC Cancer · doi:10.1186/s12885-017-3500-5 · Cited by 180
Self-citationBreakDancer: Identification of Genomic Structural Variation from Paired‐End Read Mapping
Fan, X., Abbott, T. E., Larson, D. E., & Chen, K. (2014) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1506s45 · Cited by 181
A genetic basis for the variation in the vulnerability of cancer to DNA damage
Yard, B. D., Adams, D., Chie, E. K., Tamayo, P., Battaglia, J., Gopal, P., Rogacki, K. R., Pearson, B. E., Phillips, J. G., Raymond, D. P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11428 · Cited by 188
Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models
Linnekamp, J. F., van Hooff, S. R., Prasetyanti, P. R., Kandimalla, R., Buikhuisen, J. Y., Fessler, E., Ramesh, P., Lee, K. A. S. T., Bochove, G. G. W., de Jong, J. H., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0011-5 · Cited by 182
Balanis, N. G., Sheu, K. M., Esedebe, F. N., Patel, S. J., Smith, B. A., Park, J. W., Alhani, S., Gomperts, B. N., Huang, J., Witte, O. N., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.005 · Cited by 179
In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models
Lee, S., Koo, I.-S., Hwang, H. J., & Lee, D. W. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.03.006 · Cited by 193
Voltage-gated calcium channels: Novel targets for cancer therapy
Phan, N. N., Wang, C., Chen, C., Sun, Z., Lai, M., & Lin, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6457 · Cited by 174
Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy
Nissim, L., Wu, M.-R., Pery, E., Binder-Nissim, A., Suzuki, H. I., Stupp, D., Wehrspaun, C. C., Tabach, Y., Sharp, P. A., & Lu, T. K. (2017) · Cell · doi:10.1016/j.cell.2017.09.049 · Cited by 179
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Diplas, B. H., He, X., Brosnan‐Cashman, J. A., Liu, H., Chen, L. H., Wang, Z., Moure, C. J., Killela, P. J., Loriaux, D. B., Lipp, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04448-6 · Cited by 175
Zhang, D. Y., Dmello, C., Chen, L., Arrieta, V. A., González-Buendía, E., KANE, J. R., Magnusson, L. P., Baran, A. H., James, C. D., Horbinski, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2182 · Cited by 176
Jin, H., Zhang, C., Zwahlen, M., von Feilitzen, K., Karlsson, M., Shi, M., Yuan, M., Song, X., Li, X., Yang, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41132-w · Cited by 188
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Inoue‐Yamauchi, A., Jeng, P., Kim, K., Chen, H., Han, S., Ganesan, Y. T., Ishizawa, K., Jebiwott, S., Dong, Y., Pietanza, M. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms16078 · Cited by 180
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Bartolacci, C., Andreani, C., do Vale, G. D., Berto, S., Melegari, M., Crouch, A. C., Baluya, D. L., Kemble, G. W., Hodges, K. B., Starrett, J. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31963-4 · Cited by 183
KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity
Winter, G. E., Radic, B., Mayor-Ruiz, C., Blomen, V. A., Trefzer, C., Kandasamy, R. K., Huber, K. V. M., Gridling, M., Chen, D., Klampfl, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1590 · Cited by 175
Bilir, B., Küçük, Ö., & Moreno, C. S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-280 · Cited by 175
Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment
Norton, K., Gong, C., Jamalian, S., & Popel, A. S. (2019) · Processes · doi:10.3390/pr7010037 · Cited by 178
Wang-Bishop, L., Wehbe, M., Shae, D., James, J. L., Hacker, B. C., Garland, K. M., Chistov, P. P., Rafat, M., Balko, J. M., & Wilson, J. T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000282 · Cited by 184
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lü, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 178
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target
Kolluri, S. K., Jin, U.-H., & Safe, S. H. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1981-2 · Cited by 181
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Poirier, J. T., George, J., Owonikoko, T. K., Berns, A. J. M., Brambilla, E. M., Byers, L. A., Carbone, D. P., Chen, H. J., Christensen, C. L., Dive, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.016 · Cited by 176
EP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma
Durbin, A. D., Wang, T., Wimalasena, V. K., Zimmerman, M. W., Li, D., Dharia, N. V., Mariani, L., Shendy, N. A. M., Nance, S., Patel, A. G., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0385 · Cited by 181
McFarland, J. M., Paolella, B. R., Warren, A., Geiger-Schuller, K., Shibue, T., Rothberg, M., Kuksenko, O., Colgan, W. N., Jones, A., Chambers, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17440-w · Cited by 173
Self-citationIn Vitro Human Cell Line Models to Predict Clinical Response to Anticancer Drugs
Niu, N., & Wang, L. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.170 · Cited by 177
Self-citationDecker, B. J., Parker, H. G., Dhawan, D., Kwon, E. M., Karlins, E., Davis, B. W., Ramos, J. A., Bonney, P. L., McNiel, E. A., Knapp, D. W., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0689 · Cited by 175
Tunçbağ, N., Gosline, S. J. C., Kedaigle, A. J., Soltis, A. R., Gitter, A., & Fraenkel, E. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004879 · Cited by 172
Simpson, K., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., Humphrey, S., Booth, L., Morgan, D., Dynowski, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0046-2 · Cited by 176
Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.041 · Cited by 172
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C. S. F., Momčilović, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4213 · Cited by 171
Chan-Penebre, E., Armstrong, K. A., Drew, A. E., Grassian, A. R., Feldman, I., Knutson, S. K., Kuplast-Barr, K. G., Roche, M. R., Campbell, J., Ho, P. T. C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0678 · Cited by 172
Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Mao, P., Cohen, O., Kowalski, K. J., Kusiel, J. G., Buendia-Buendia, J. E., Cuoco, M. S., Exman, P., Wander, S. A., Waks, A. G., Nayar, U., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3958 · Cited by 171
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Basilico, C., Pennacchietti, S., Vigna, E., Chiriaco, C., Arena, S., Bardelli, A., Valdembri, D., Serini, G., & Michieli, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3459 · Cited by 171
Lau, J. W., Lehnert, E. M., Sethi, A., Malhotra, R., Kaushik, G. N., Onder, Z., Groves-Kirkby, N., Mihajlović, A., DiGiovanna, J., Srdic, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0387 · Cited by 171
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Harris, I. S., Endress, J. E., Coloff, J. L., Selfors, L. M., McBrayer, S. K., Rosenbluth, J. M., Takahashi, N., Dhakal, S., Koduri, V., Oser, M. G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.020 · Cited by 171
Li, Z., Zhu, S., Shao, B., Zeng, X., Wang, T., & Liu, T. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac597 · Cited by 176
Jang, I. S., Neto, E. C., Guinney, J., Friend, S. H., & Margolin, A. A. (2014) · PubMed · Cited by 170
Self-citationApplications in image-based profiling of perturbations
Caicedo, J. C., Singh, S., & Carpenter, A. E. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.04.003 · Cited by 169
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Bailey, P. J., Chang, D. K.-F., Forget, M., Lucas, F. A. S., Alvarez, H. A., Haymaker, C., Chattopadhyay, C., Kim, S.-H., Ekmekçioglu, S., Grimm, E. A., et al. (2016) · Scientific Reports · doi:10.1038/srep35848 · Cited by 172
Self-citationMachine learning and image-based profiling in drug discovery
Scheeder, C., Heigwer, F., & Boutros, M. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.05.004 · Cited by 167
Mouse models of colorectal cancer: Past, present and future perspectives
Bürtin, F., Mullins, C. S., & Linnebacher, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i13.1394 · Cited by 183
An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
Maertens, O., & Cichowski, K. M. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.002 · Cited by 171
Nogales, V., Reinhold, W. C., Varma, S., Martínez‐Cardús, A., Moutinho, C., Morán, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y. G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 176
Fu, X., Jeselsohn, R. M., Pereira, R., Hollingsworth, E. F., Creighton, C. J., Li, F., Shea, M. J., Nardone, A., Angelis, C. D., Heiser, L. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612835113 · Cited by 172
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2012) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 180
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
Self-citationJeon, J., Nim, S., Teyra, J., Datti, A., Wrana, J. L., Sidhu, S. S., Moffat, J., & Kim, P. M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0057-7 · Cited by 174
Bader, D. A., Hartig, S. M., Putluri, V., Foley, C., Hamilton, M. P., Smith, E. A., Saha, P., Panigrahi, A., Walker, C. M., Zong, L., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0002-y · Cited by 168
Identifying compound efficacy targets in phenotypic drug discovery
Schirle, M., & Jenkins, J. L. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.001 · Cited by 166
Metadata
- Authors
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F., Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jané-Valbuena, J., Mapa, F. A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G., Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P., Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Harvard University (US)
- Corresponding author
- Schlegel, Robert
- Garraway, Levi A.
- ORCID
- Barretina, Jordi
- Stransky, Nicolas
- Venkatesan, Kavitha
- Wilson, Christopher J.
- Lehár, Joseph
- Kryukov, Gregory V.
- Sonkin, Dmitriy
- Reddy, Anupama
- Liu, Manway
- Murray, Lauren
- Berger, Michael F.
- Monahan, John E.
- Mapa, Felipa A.
- Raman, Pichai
- Yu, Guoying K.
- Yu, Jianjun
- Aspesi, Peter
- Jones, Michael D.
- Wang, Li
- Gupta, Supriya
- Liefeld, Ted
- MacConaill, Laura
- Winckler, Wendy
- Reich, Michael
- Li, Nanxin
- Mesirov, Jill P.
- Gabriel, Stacey B.
- Getz, Gad
- Ardlie, Kristin
- Chan, Vivien
- Myer, Vic E.
- Weber, Barbara L.
- Meyerson, Matthew
- Golub, Todd R.
- Sellers, William R.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 603-607
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3320027
- OpenAlex
- W2043398720
- Cited by
- 7,950
- References
- 28
- Citations by year
- 2026: 361 · 2025: 501 · 2024: 617 · 2023: 719 · 2022: 723 · 2021: 839 · 2020: 682 · 2019: 687 · 2018: 628 · 2017: 500 · 2016: 516 · 2015: 436 · 2014: 348 · 2013: 283 · 2012: 103
- FWCI
- 124.24
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R33CA155554, R33CA126674)
- National Institute of General Medical Sciences (R01GM074024)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Cancer Cell Line Encyclopedia, anticancer drug sensitivity, drug resistance, cancer cell lines, Ewing sarcoma, PARP inhibitors, SLFN11, topoisomerase inhibitors, MEK inhibitors, NRAS mutation, aryl hydrocarbon receptor, gene expression profiles, chromosomal copy number, predictive modeling, precision oncology
- MeSH terms
- Antineoplastic Agents, Chromosomes, Human, Clinical Trials as Topic, Drug Screening Assays, Antitumor, Encyclopedias as Topic, Humans, Models, Biological, Neoplasms, Pharmacogenetics, Plasma Cells, Genes, ras, Genome, Human, Gene Expression Regulation, Neoplastic, Databases, Factual, Sequence Analysis, DNA, Receptor, IGF Type 1, Receptors, Aryl Hydrocarbon, Cell Lineage, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Genomics, Cell Line, Tumor, Precision Medicine, Topoisomerase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
